Download Champions' latest AACR 2022 Poster

A Pharmaco-Pheno-Multiomic Integration Analysis of Primary Acute Myeloid Leukemia (AML) Reveals Biomarkers of Cytarabine Resistance 

This study explores the molecular mechanisms underlying therapeutic resistance in Acute Myeloid Leukemia (AML) by integrating tumor phenotyping, drug sensitivity profiling, and multiomic data. The analysis reveals key biomarkers and molecular features associated with drug response, specifically cytarabine. By leveraging pharmaco-phenotypic-multiomic (PPMO) integration, the study identifies potential targets for improving long-term outcomes in AML treatment.

• Comprehensive tumor phenotyping, drug sensitivity profiling, and multiomic data were integrated to uncover AML resistance mechanisms.

• CD34 expression was found to correlate with cytarabine sensitivity, while CD34-negative phenotypes were linked to resistance.

• The PPMO model accurately predicted drug response profiles for additional AML samples, suggesting its potential as a predictive diagnostic tool.